Invasive aspergillosis in liver transplant recipients in France (2007-21): a nationwide, retrospective, matched case-control study

Lancet Microbe. 2026 Apr;7(4):101272. doi: 10.1016/j.lanmic.2025.101272. Epub 2026 Mar 2.

Abstract

Background: Invasive aspergillosis is a rare but severe complication of liver transplantation. Incidence varies from 1·2% to 5·6% and mortality is greater than 50%. Few studies have investigated this complication. We aimed to describe cases of, and identify the factors associated with, invasive aspergillosis occurrence and mortality.

Methods: This nationwide, retrospective, matched case-control study included cases of invasive aspergillosis occurring after liver transplantation between Jan 1, 2007, and Dec 31, 2021, matched 1:1 on centre and transplantation period to control individuals without invasive aspergillosis across 15 liver transplantation centres in France. Cases were patients aged 18 years or older who presented with proven or probable invasive aspergillosis. The matched control was the next patient who received a transplant at the same transplantation centre after the case. Cases were retrospectively identified in each centre using the mycology laboratory database and the French Medicalised Information System Programme. Data were retrieved from hospital charts. The primary outcome was the identification of risk factors associated with the development of invasive aspergillosis following liver transplantation. Multivariable analysis using conditional logistic regression with a random effect for study centres was done to establish risk factors.

Findings: Among 14 332 liver transplantations, 196 recipients with invasive aspergillosis (62 [32%] female and 134 [68%] male) were identified and matched with 196 control individuals (54 [28%] female and 142 [73%] male). Invasive aspergillosis occurred at a median of 29 days (IQR 7-173) after liver transplantation. Risk factors for developing invasive aspergillosis were history of chronic kidney disease (adjusted odds ratio 4·13 [95% CI 2·35-7·24]), liver transplantation for acute liver disease (3·41 [1·44-8·06]), post-liver transplantation renal replacement therapy (3·82 [1·96-7·42]), and post-liver transplantation vasopressor support for longer than 24 h (2·82 [1·70-4·68]).

Interpretation: This study identifies three patient populations at risk of invasive aspergillosis after liver transplantation: patients with history of chronic kidney disease, those who have received a transplant for acute liver disease, and those who had a post-operative period marked by organ failure. This identification could lead to new invasive aspergillosis prophylactic strategies.

Funding: None.

MeSH terms

  • Adult
  • Aged
  • Aspergillosis* / epidemiology
  • Aspergillosis* / mortality
  • Case-Control Studies
  • Female
  • France / epidemiology
  • Humans
  • Incidence
  • Liver Transplantation* / adverse effects
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Transplant Recipients* / statistics & numerical data